Altre lingue Cytosorbents Corporation

Azioni

CTSO

US23283X2062

Tempo differito Nasdaq Altri mercati azionari 15:44:16 07/06/2024			Variaz. 5gg	Var. 1 gen.
0,89 ^USD	+0,46%		-1,12%	-19,82%

09/05	Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024
09/05	Cytosorbents Corporation riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting	05/06
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract	04/06
Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M	09/05
CytoSorbents: Q1 Earnings Snapshot	09/05
CytoSorbents Reports First Quarter 2024 Results	09/05
Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe	02/05
CytoSorbents to Report First Quarter 2024 Operating and Financial Results	26/04
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting	17/04
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	14/03
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results	14/03
CytoSorbents to Report Fiscal 2023 Operating and Financial Results	06/03
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	08/02
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	08/02
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	31/01
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	23/01
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	17/01
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	17/01
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	17/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cytosorbents Corporation

Azioni

CTSO

US23283X2062

Altre lingue

Filtri